Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Lakewood-Amedex Biotherapeutics (LABT) will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lakewood-Amedex Biotherapeutics (LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City.
CEO Kelvin Cooper, Ph.D., will deliver a virtual presentation on the company’s Bisphosphocin® antimicrobial platform. During the conference, he will also hold one-on-one meetings with registered investors and potential partners to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Details
News Market Reaction – LABT
On Sep 8, the day this news came out, LABT closed 15.96% above the previous close. Argus tracked a peak move of +22.1% during that session. Our momentum scanner recorded 28 alerts for this stock that day. Relative volume reached 6.4x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Details of the presentation are as follows:
Event: | H.C. Wainwright 28th Annual Global Investment Conference |
Date: | September 14-16, 2026 |
During the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-to-present-at-hc-wainwright-28th-annual-global-investment-conference-302872149.html
SOURCE Lakewood-Amedex Biotherapeutics Inc.